- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02268383
ACE-536 Extension Study - Myelodysplastic Syndromes
April 29, 2021 updated by: Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 for the Treatment of Anemia in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Previously Enrolled in Study A536-03
Study A536-05 is an open-label extension study for patients previously enrolled in study A536-03 (ClinicalTrials.gov
Identifier NCT01749514), to evaluate the long-term safety and tolerability of ACE-536 in patients with low or intermediate-1 risk MDS.
Study Overview
Detailed Description
Study A536-05 is an open-label extension study to evaluate the safety, tolerability, and pharmacodynamic effects of up to 24 months of ACE-536 treatment in patients with low or intermediate-1 risk myelodysplastic syndromes previously treated with ACE-536 for up to 3 months in study A536-03 (ClinicalTrials.gov
Identifier NCT01749514).
The starting dose level in study A536-05 will be 1.0 mg/kg by subcutaneous (SC) injection every 3 weeks.
Dose titration/modification rules will be followed for individual patients and will be based upon safety and efficacy data collected during the course of treatment.
Study Type
Interventional
Enrollment (Actual)
75
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dresden, Germany
- Acceleron Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Completion of the treatment period in the base study A536-03 (ClinicalTrials.gov Identifier:
NCT01749514)
- Adequate birth control measures
- Patient is able to adhere to the study visit schedule, understand and comply with all protocol requirements.
- Patient understands and is able to provide written informed consent.
In addition, patients with treatment interruption (defined as patients who complete their end-of-study visit in A536-03 and cannot directly roll over to A536-05) must also meet the following criteria:
- Documented diagnosis of idiopathic/de novo MDS or non-proliferative chronic myelomonocytic leukemia (CMML) according to the World Health Organization (WHO) criteria 2 (white blood count (WBC) < 13,000/μL) that meets International Prognostic Scoring System (IPSS) classification (Appendix 2) of low or intermediate-1 risk disease as determined by microscopic and standard cytogenetic analyses of the bone marrow and peripheral complete blood count (CBC) obtained during screening;
- Anemia defined as:
- Mean hemoglobin concentration < 10.0 g/dL of 2 measurements (one performed within one day prior to Cycle 1 Day 1 and the other performed 7-28 days prior to Cycle 1 Day 1), for non-transfusion dependent (NTD) patients (defined as having received ˂ 4 units of red blood cells (RBCs) within 8 weeks prior to Cycle 1 Day 1), OR
- Transfusion Dependent (TD), defined as having received ≥ 4 units of RBCs within 8 weeks prior to Cycle 1 Day 1.
- Platelet count ≥ 30 x 109/L
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 (if related to anemia)
- Adequate renal (creatinine ≤ 2.0 x upper limit of normal [ULN]) and hepatic (total bilirubin < 2 x ULN and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN) function
Exclusion Criteria:
- Discontinuation/withdrawal from the base study A536-03 (due to patient request, patient unwillingness or inability to comply with the protocol, pregnancy, use of prohibited medication [e.g. azacitidine], medical reason or adverse event (AE), hypersensitivity reaction to the study drug, at the discretion of the sponsor, or loss to follow-up) prior to completion of the treatment period
- Prior treatment with azacitidine or decitabine
- Treatment within 28 days prior to Cycle 1 Day 1 with:
- an erythropoiesis-stimulating agent (ESA),
- Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF),
- Lenalidomide
- Iron chelation therapy if initiated within 56 days prior to Cycle 1 Day 1
- Treatment with another investigational drug (including sotatercept [ACE-011]) or device, or approved therapy for investigational use ≤ 28 days prior to Cycle 1 Day 1, or if the half-life of the previous investigational product is known, within 5 times the half-life prior to Cycle 1 Day 1, whichever is longer
- Major surgery within 28 days prior to Cycle 1 Day 1. Patients must have completely recovered from any previous surgery prior to Cycle 1 Day 1
- Known positive for human immunodeficiency virus (HIV), active infectious hepatitis B (HBV) or active infectious hepatitis C (HCV)
- Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 150 mm Hg or diastolic blood pressure (DBP) ≥ 100 mm Hg
- Pregnant or lactating females
- History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational drug
- Any other condition not specifically noted above which, in the judgment of the investigator, would preclude the patient from participating in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ACE-536
ACE-536 1.0 mg/kg once every 3 weeks by subcutaneous injection.
|
ACE-536 1.0 mg/kg once every 3 weeks by subcutaneous injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the long-term safety and tolerability of ACE-536 in patients with low or intermediate-1 risk MDS who were previously enrolled in study A536-03
Time Frame: From first dose (Study Day1) to end of treatment (Study Day 730)
|
From first dose (Study Day1) to end of treatment (Study Day 730)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rates of erythroid, neutrophil and platelet (HI-E, HI-N and HI-P) responses.
Time Frame: Measured during any 8 week period on study, up to 28 weeks from patient screening, compared with the 8-week period prior to study day 1.
|
Measured during any 8 week period on study, up to 28 weeks from patient screening, compared with the 8-week period prior to study day 1.
|
|
Erythroid response in non-transfusion dependent (NTD) patients
Time Frame: From first dose (Study Day1) to end of treatment (Study Day 730)
|
Proportion of patients with a mean hemoglobin (Hgb) increase ≥ 1.5 g/dL over an 8-week period as compared to baseline, not influenced by red blood cell (RBC) transfusion
|
From first dose (Study Day1) to end of treatment (Study Day 730)
|
Erythroid response in transfusion dependent (TD) patients
Time Frame: From first dose (Study Day1) to end of treatment (Study Day 730)
|
Proportion of patients with a decrease of ≥ 4 units or ≥ 50% of units of red blood cells (RBCs) transfused over a period of 8 weeks, relative to the 8 weeks immediately prior to Day 1
|
From first dose (Study Day1) to end of treatment (Study Day 730)
|
Proportion of TD patients who become transfusion independent
Time Frame: From first dose (Study Day1) to end of treatment (Study Day 730)
|
Defined as patients requiring no RBC transfusion for a period of ≥ 8 weeks
|
From first dose (Study Day1) to end of treatment (Study Day 730)
|
Time to, and duration of, erythroid response in NTD and TD patients
Time Frame: From first dose (Study Day1) to end of treatment (Study Day 730)
|
From first dose (Study Day1) to end of treatment (Study Day 730)
|
|
Mean mean change in RBC transfusion burden (#RBC units/8 weeks) in TD patients
Time Frame: From first dose (Study Day1) to end of treatment (Study Day 730)
|
From first dose (Study Day1) to end of treatment (Study Day 730)
|
|
Mean change in hemoglobin levels in NTD patients
Time Frame: From first dose (Study Day1) to end of treatment (Study Day 730)
|
From first dose (Study Day1) to end of treatment (Study Day 730)
|
|
ACE-536 pharmacokinetic profile (Tmax, Cmax and AUC)
Time Frame: From first dose (Study Day1) to end of treatment (Study Day 730)
|
From first dose (Study Day1) to end of treatment (Study Day 730)
|
|
Change from baseline in markers of erythropoiesis
Time Frame: From first dose (Study Day1) to end of treatment (Study Day 730)
|
From first dose (Study Day1) to end of treatment (Study Day 730)
|
|
Change from baseline in markers of iron metabolism
Time Frame: From first dose (Study Day1) to end of treatment (Study Day 730)
|
From first dose (Study Day1) to end of treatment (Study Day 730)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Platzbecker U, Gotze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, Oelschlagel U, Haase D, Illmer T, Al-Ali HK, Silling G, Reynolds JG, Zhang X, Attie KM, Shetty JK, Giagounidis A. Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study. J Clin Oncol. 2022 Nov 20;40(33):3800-3807. doi: 10.1200/JCO.21.02476. Epub 2022 Aug 23.
- Platzbecker U, Germing U, Gotze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1. Erratum In: Lancet Oncol. 2017 Oct;18(10):e562.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2014
Primary Completion (Actual)
May 18, 2020
Study Completion (Actual)
May 18, 2020
Study Registration Dates
First Submitted
October 6, 2014
First Submitted That Met QC Criteria
October 16, 2014
First Posted (Estimate)
October 20, 2014
Study Record Updates
Last Update Posted (Actual)
May 4, 2021
Last Update Submitted That Met QC Criteria
April 29, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A536-05
- 2014-001280-13 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
I-Mab Biopharma Co. Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
Clinical Trials on ACE-536
-
M.D. Anderson Cancer CenterRecruitingMyelodysplastic SyndromesUnited States
-
CelgeneActive, not recruitingMyelodysplastic SyndromesChina, Japan
-
CelgeneCompletedPrimary Myelofibrosis | AnemiaUnited States, France, Italy, United Kingdom
-
CelgeneAcceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...CompletedBeta-Thalassemia | Erythrocyte TransfusionUnited States, Israel, Australia, Turkey, Taiwan, Malaysia, United Kingdom, Canada, Thailand, France, Lebanon, Italy, Bulgaria, Greece, Tunisia
-
CelgeneAcceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...CompletedMyelodysplastic SyndromesCanada, United States, Germany, Belgium, France, United Kingdom, Turkey, Spain, Italy, Netherlands, Sweden
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Completed
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbRecruitingMyelodysplastic Syndromes | Anemia | Myeloproliferative NeoplasmUnited States
-
Bristol-Myers SquibbRecruiting
-
CelgeneAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...RecruitingBeta-ThalassemiaUnited States, Turkey, Italy, Thailand, Germany, Greece
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Completed